Economic implications of cardiovascular disease management programs: moving beyond one-off experiments

References

• What is Cardiovascular disease?. Australian government department of health. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/chronic-cardio [Last accessed 14 May 2014]
   Google Scholar
• Johnson A. Measuring DM’s net effect is harder than you might think. Managed care 2003;12:28-32
   Google Scholar
• Mark DB, Hlatky MA. Medical Economics and the Assessment of Value in Cardiovascular Medicine: Part II. Circulation 2002;106:626-30
   PubMed Web of Science ®Google Scholar
• Mohler R, Bartoszek G, Meyer G. Quality of reporting of complex healthcare interventions and applicability of the CReDECI list - a survey of publications indexed in PubMed. BMC Med Res Methodol 2013;13:125
   Google Scholar
• Maru S, Byrnes J, Carrington MJ, et al. Systematic review of trial-based analyses reporting the economic impact of heart failure management programs compared with usual care. Eur J Cardiovasc Nurs 2014. [Epub ahead of print]
   Google Scholar
• Maru S, Byrnes J, Whitty JA, et al. Systematic review of model-based analyses reporting the cost-effectiveness and cost-utility of cardiovascular disease management programs. Eur J Cardiovasc Nurs 2015;14:26-33
   PubMed Web of Science ®Google Scholar
• Feltner C, Jones CD, Cené CW, et al. Transitional Care Interventions to Prevent Readmissions for Persons With Heart Failure. A Systematic Review and Meta-analysisTransitional Care for Persons With Heart Failure. Ann Intern Med 2014;160:774-84
   PubMed Web of Science ®Google Scholar
• Angermann CE, Störk S, Gelbrich G, et al. Mode of action and effects of standardized collaborative disease management on mortality and morbidity in patients with systolic heart failure: the interdisciplinary network for heart failure (INH) study. Circulation Heart Failure 2012;5:25-35
   PubMed Web of Science ®Google Scholar
• Gillespie P, O’Shea E, Murphy AW, et al. The cost-effectiveness of the SPHERE intervention for the secondary prevention of coronary heart disease. Int J Technol Assess Health Care 2010;26:263-71
   Google Scholar
• Gillespie P, O’Shea E, Murphy AW, et al. Relative cost effectiveness of the SPHERE intervention in selected patient subgroups with existing coronary heart disease. Eur J Health Econ 2012;13:429-43
   Google Scholar
• Riegel B, Lee CS, Sochalski J. Developing an Instrument to Measure Heart Failure Disease Management Program Intensity and Complexity. Circulation 2010;3:324-30
   Google Scholar
• Del Sindaco D, Pulignano G, Minardi G, et al. Two-year outcome of a prospective, controlled study of a disease management programme for elderly patients with heart failure. J Cardiovasc Med (Hagerstown) 2007;8:324-9
   PubMed Web of Science ®Google Scholar
• Pulignano G, Del Sindaco D, Di Lenarda A, et al. Usefulness of frailty profile for targeting older heart failure patients in disease management programs: a cost-effectiveness, pilot study. J Cardiovasc Med (Hagerstown) 2010;11:739-47
   PubMed Web of Science ®Google Scholar
• Galbreath AD, Krasuski RA, Smith B, et al. Long-term healthcare and cost outcomes of disease management in a large, randomized, community-based population with heart failure. Circulation 2004;110:3518-26
   PubMed Web of Science ®Google Scholar
• Smith B, Hughes-Cromwick PF, Forkner E, et al. Cost-effectiveness of telephonic disease management in heart failure. Am J Manag Care 2008;14:106-15
   PubMed Web of Science ®Google Scholar
• Miller G, Randolph S, Forkner E, et al. Long-term cost-effectiveness of disease management in systolic heart failure. Med Decis Making 2009;29:325-33
   PubMed Web of Science ®Google Scholar
• Campbell and Cochrane Economics Methods Group and the Evidence for Policy and Practice Information and Coordinating Centre. ‘CCEMG – EPPI-Centre Cost Converter’. Available from: http://eppi.ioe.ac.uk/costconversion/default.aspx [Last accessed 4 November 2014]
   Google Scholar
• D’Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000;139:272-81
   PubMed Web of Science ®Google Scholar
• Satagopan JM, Ben-Porat L, Berwick M, et al. A note on competing risks in survival data analysis. Br J Cancer 2004;91:1229-35
   PubMed Web of Science ®Google Scholar
• Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695-706
   PubMed Web of Science ®Google Scholar
• Krumholz HM, Weintraub WS, Bradford WD, et al. Task force #2--the cost of prevention: can we afford it? Can we afford not to do it? 33rd Bethesda Conference. J Am Coll Cardiol 2002;40:603-15
   Google Scholar
• Dunagan WC, Littenberg B, Ewald GA, et al. Randomized trial of a nurse-administered, telephone-based disease management program for patients with heart failure. J Card Fail 2005;11:358-65
   Google Scholar
• Kasper EK, Gerstenblith G, Hefter G, et al. A randomized trial of the efficacy of multidisciplinary care in heart failure outpatients at high risk of hospital readmission. J Am Coll Cardiol 2002;39:471-80
   PubMed Web of Science ®Google Scholar
• Michalsen A, Konig G, Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart 1998;80:437-41
   PubMed Web of Science ®Google Scholar
• Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 2003;42:1226-33
   PubMed Web of Science ®Google Scholar
• Culler SD, Parchman ML, Przybylski M. Factors Related to Potentially Preventable Hospitalizations Among the Elderly. Med Care 1998;36:804-17
   PubMed Web of Science ®Google Scholar
• Maslow K, Ouslander JG. Measurement of potentially preventable hospitalizations (a white paper); The Long-term Quality Alliance. Available from: www.ltqa.org/2012-02-16-ltqa-white-paper-offers-guidance-for-long-term-care-organizations-to-measure-preventable-hospitalizations.html [Last accessed 10 November 2014]
   Google Scholar
• Goldfield NI, McCullough EC, Hughes JS, et al. Identifying potentially preventable readmissions. Health Care Financ Rev 2008;30:75-91
   PubMed Web of Science ®Google Scholar
• Atienza F, Anguita M, Martinez-Alzamora N, et al. Multicenter randomized trial of a comprehensive hospital discharge and outpatient heart failure management program. Eur J Heart Fail 2004;6:643-52
   PubMed Web of Science ®Google Scholar
• Stewart S, Pearson S, Horowitz JD. Effects of a home-based intervention among patients with congestive heart failure discharged from acute hospital care. Arch Intern Med 1998;158:1067-72
   PubMed Web of Science ®Google Scholar
• Stewart S, Marley JE, Horowitz JD. Effects of a multidisciplinary, home-based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure: a randomised controlled study. Lancet 1999;354:1077-83
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Cohen JT. Cost savings and cost-effectiveness of clinical preventive care. Syn Project Res Syn Report 2009(18):48508
   Google Scholar
• Gandjour A, Lauterbach KW. Does prevention save costs? Considering deferral of the expensive last year of life. J Health Econ 2005;24:715-24
   PubMed Web of Science ®Google Scholar
• Conklin A, Nolte E. Disease management evaluation (A comprehensive review of current state of the art). RAND Corp 2010
   Google Scholar
• Nolte E, Annalijn C, John L, et al. Evaluating chronic disease management: Recommendations for funders and users. RAND Corporation, Santa Monica, CA; 2012. Available from: http://www.rand.org/pubs/technical_reports/TR1213
   Google Scholar
• Murray MD, Young J, Hoke S, et al. Pharmacist intervention to improve medication adherence in heart failure: a randomized trial. Ann Intern Med 2007;146:714-25
   PubMed Web of Science ®Google Scholar
• Lopez Cabezas C, Falces Salvador C, Cubi Quadrada D, et al. Randomized clinical trial of a postdischarge pharmaceutical care program vs regular follow-up in patients with heart failure. Farm 2006;30:328-42
   PubMedGoogle Scholar
• Yu J, Shah BM, Ip EJ, et al. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California. J Manag Care Pharm 2013;19:102-14
   PubMed Web of Science ®Google Scholar
• A Dictionary of Epidemiology, Third Edition; Edited by John M. Last 1995
   Google Scholar
• Casteels M, Flamion B. Open-label trials and drug registration: a European regulator’s view. J Thromb Haemost 2008;6:232-4
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J, Buller H. External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different? J Thromb Haemost 2011;9:2153-8
   PubMed Web of Science ®Google Scholar
• Nolte E, Conklin A, Adams JL, et al. Evaluating chronic disease management. RAND Corporation 2012
   Google Scholar
• Murphy AW, Cupples ME, Smith SM, et al. Effect of tailored practice and patient care plans on secondary prevention of heart disease in general practice: cluster randomised controlled trial. BMJ 2009;339:b4220
   Google Scholar
• Jafar TH, Islam M, Bux R, et al. Cost-effectiveness of community-based strategies for blood pressure control in a low-income developing country: findings from a cluster-randomized, factorial-controlled trial. Circulation 2011;124:1615-25
   PubMed Web of Science ®Google Scholar
• Shiell A, Hawe P, Gold L. Complex interventions or complex systems? Implications for health economic evaluation. BMJ 2008;336:1281-3
   PubMed Web of Science ®Google Scholar
• Pawson R, Greenhalgh T, Harvey G, et al. Realist review-a new method of systematic review designed for complex policy interventions. J Health Serv Res Policy 2005;10(Suppl 1):21-34
   PubMedGoogle Scholar
• Clark AM, Briffa TG, Thirsk L, et al. What football teaches us about researching complex health interventions. BMJ 2012;345:e8316
   PubMed Web of Science ®Google Scholar
• Clark AM. What are the components of complex interventions in healthcare? Theorizing approaches to parts, powers and the whole intervention. Soc Sci Med 2013;93:185-93
   PubMed Web of Science ®Google Scholar
• Glouberman S, Zimmermann B. Complicated and complex systems: what would successful reform of medicare look like? Commission on the Future of Health Care in Canada. Available from: http://www.alnap.org/resource/8119 [Last accessed 1 March 2015]
   Google Scholar
• Reed SD, Li Y, Kamble S, et al. Introduction of the tools for economic analysis of patient management interventions in heart failure costing tool: a user-friendly spreadsheet program to estimate costs of providing patient-centered interventions. Circ Cardiovasc Qual Outcomes 2012;5:113-19
   PubMed Web of Science ®Google Scholar
• Graves N, Walker D, Raine R, et al. Cost data for individual patients included in clinical studies: no amount of statistical analysis can compensate for inadequate costing methods. Health Econ 2002;11:735-9
   Google Scholar
• Briggs A, Claxton K, Sculpher M, et al. Decision modelling for health economic evaluation. Oxford University Press; 2006
   Google Scholar
• Briggs AH, O’Brien BJ. The death of cost-minimization analysis? Health Econ 2001;10:179-84
   PubMed Web of Science ®Google Scholar
• Johnston K, Gray A, Moher M, et al. Reporting the cost-effectiveness of interventions with nonsignificant effect differences: example from a trial of secondary prevention of coronary heart disease. Int J Technol Assess Health Care 2003;19:476-89
   PubMed Web of Science ®Google Scholar
• Drummond M, Sculpher M, Torrance G, et al. Methods for the economic evaluation of health care programmes. 3 edition. Oxford University Press; New York: 2005
   Google Scholar
• Gray A, Clarke P, Wolstenholme J, et al. Applied Methods of Cost-effectiveness Analysis in Healthcare. Oxford University Press, New York; 2011
   Google Scholar
• Annema C, Luttik ML, Jaarsma T. Do Patients With Heart Failure Need a Case Manager? J Cardiovasc Nurs 2009;24:127-31
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMC Med 2013;11:80
   PubMed Web of Science ®Google Scholar
• Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Available from: www.bmj.com/content/346/bmj.f1049
   Google Scholar
• TEAM-HF. Available from: www.team-hf.com
   Google Scholar
• Boutron I, Moher D, Altman DG, et al. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med 2008;148:295-309
   PubMed Web of Science ®Google Scholar
• Krumholz H, Currie P, Riegel B, et al. A taxonomy for disease management: a scientific statement from the american heart association disease management taxonomy writing group. Circulation 2006;114:1432-45
   PubMedGoogle Scholar